WO2001017958A3 - Neuropeptide sf receptor assays, compounds and therapeutic methods - Google Patents

Neuropeptide sf receptor assays, compounds and therapeutic methods Download PDF

Info

Publication number
WO2001017958A3
WO2001017958A3 PCT/US2000/024447 US0024447W WO0117958A3 WO 2001017958 A3 WO2001017958 A3 WO 2001017958A3 US 0024447 W US0024447 W US 0024447W WO 0117958 A3 WO0117958 A3 WO 0117958A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
compounds
neuropeptide
therapeutic methods
receptor assays
Prior art date
Application number
PCT/US2000/024447
Other languages
French (fr)
Other versions
WO2001017958A2 (en
WO2001017958A9 (en
Inventor
Qingyun Liu
Terrence P Mcdonald
Wendy J Bailey
Marlene Jacobson
John Mallee
Zhizhen Zeng
Original Assignee
Merck & Co Inc
Qingyun Liu
Terrence P Mcdonald
Wendy J Bailey
Marlene Jacobson
John Mallee
Zhizhen Zeng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Qingyun Liu, Terrence P Mcdonald, Wendy J Bailey, Marlene Jacobson, John Mallee, Zhizhen Zeng filed Critical Merck & Co Inc
Publication of WO2001017958A2 publication Critical patent/WO2001017958A2/en
Publication of WO2001017958A3 publication Critical patent/WO2001017958A3/en
Publication of WO2001017958A9 publication Critical patent/WO2001017958A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors

Abstract

The present invention provides assays for the identification of compounds that interact with the HG31 receptor. The assays take advantage of the discovery that NPSF or a related neuropeptide is a high affinity ligand of HG31 that activates the receptor upon binding thereto. The present invention also provides compounds identified as agonists or antagonists of the HG31 receptor, and methods of treatment of eating disorders by modulating HG31 receptor activity.
PCT/US2000/024447 1999-09-10 2000-09-06 Neuropeptide sf receptor assays, compounds and therapeutic methods WO2001017958A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15343699P 1999-09-10 1999-09-10
US60/153,436 1999-09-10

Publications (3)

Publication Number Publication Date
WO2001017958A2 WO2001017958A2 (en) 2001-03-15
WO2001017958A3 true WO2001017958A3 (en) 2002-05-23
WO2001017958A9 WO2001017958A9 (en) 2002-11-28

Family

ID=22547220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024447 WO2001017958A2 (en) 1999-09-10 2000-09-06 Neuropeptide sf receptor assays, compounds and therapeutic methods

Country Status (1)

Country Link
WO (1) WO2001017958A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448938B1 (en) * 2001-06-12 2002-09-10 Tantivy Communications, Inc. Method and apparatus for frequency selective beam forming
CA2698971A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of urodilatin as a therapeutic agent
WO2009033812A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent
RU2010113981A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) APPLICATION OF A HEXAPEPTIDE ANTAGONIST RECEPTOR OF THROMBOCITARY FIBRINOGEN AND ALPHA-ENDORPHINE AS A THERAPEUTIC
AU2008303909A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of Tyr-w-Mif-1 and urocortin 2 as therapeutic agents
CN108976287B (en) * 2018-08-15 2020-07-31 兰州大学 Disulfide bond cyclized analog of opioid and neuropeptide FF receptor multi-target molecule BN-9 and preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PERRY ET AL.: "A human gene encoding morphine modulating peptides related to NPFF and FMRFamide", FEBS LETTERS, vol. 406, no. 3, 16 June 1997 (1997-06-16), pages 426 - 430, XP002907620 *
VILIM ET AL.: "Gene for pain modulatory neuropeptide NPFF: Induction in spinal cord by noxious stimuli", MOLECULAR PHARMACOLOGY, vol. 55, no. 5, May 1999 (1999-05-01), pages 804 - 811, XP002907621 *

Also Published As

Publication number Publication date
WO2001017958A2 (en) 2001-03-15
WO2001017958A9 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
WO2000006085A3 (en) Compounds and methods
WO2001036365A3 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
DE69821132T2 (en) 1,3-THIAZOLE AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR TREATING ASTHMA, ALLERGIES AND DIABETES
WO2001016114A3 (en) Heterocyclic compounds and methods for modulating cxcr3 function
WO2003050295A3 (en) Assays and implements for determining and modulating hsp90 binding activity
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
WO2001016133A3 (en) 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
HK1047580A1 (en) Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes.
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
WO2002002525A3 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
MXPA03009644A (en) 1 substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor antagonists).
WO2002032374A3 (en) Methods for treating il-18 mediated disorders
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HUP0200803A2 (en) Substituted bicyclic heteroaryl compounds as integrin antagonists, pharmaceutical compositions containing them and the intermediates
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
WO2000013650A3 (en) Neuroprotection
WO1999057140A3 (en) Growth-associated protease inhibitor heavy chain precursor
CA2338066A1 (en) Treatment of dyskinesia
WO2001017958A3 (en) Neuropeptide sf receptor assays, compounds and therapeutic methods
WO2002039118A8 (en) Screening methods for bone morphogenetic mimetics
WO2001046455A3 (en) Survivin promotion of angiogenesis
ZA200203909B (en) Bicyclic cannabinoid agonists for the cannabinoid receptor.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP